BC
ITCI

Bridgefront Capital’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Bridgefront Capital’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-3,943
Closed -$205K – 589
2023
Q3 		$205K Buy
+3,943
New +$230K 0.14% 315

Other funds holding ITCI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bridgefront Capital's ITCI Position: Q4 2023 in Review

Bridgefront Capital sold out of Intra-Cellular Therapies Inc. (ITCI) in Q4 2023, closing a stake of 3,943 shares — an estimated $205K sold.

Bridgefront Capital first reported a position in ITCI in Q3 2023 and held it in 1 quarter. The position peaked at $205K in Q3 2023. 333 funds tracked by Wall St. Rank hold ITCI as of Q4 2023.

  • Bridgefront Capital reported no remaining Intra-Cellular Therapies Inc. position as of Q4 2023 after selling out during the quarter.
  • Bridgefront Capital sold 3,943 Intra-Cellular Therapies Inc. shares in Q4 2023, an estimated $205K.
  • Bridgefront Capital first reported a position in Intra-Cellular Therapies Inc. in Q3 2023 and held it in 1 quarter.
  • Bridgefront Capital's Intra-Cellular Therapies Inc. position peaked at $205K in Q3 2023.
  • 333 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q4 2023.

Based on Bridgefront Capital's 13F filing for Q4 2023, filed 14 Feb 2024.